Is Preclinical Obesity a Problematic Concept?

Key Takeaways

• Study: 261,408 treated patients, up to 33% fit preclinical definition
• Preclinical label may let payers deny obesity care
• BMI alone insufficient; comprehensive assessment needed for treatment decisions
• Experts urge definitions that expand, not restrict, patient access

Pulse Analysis

The Lancet Commission’s proposal to split obesity into “clinical” and “preclinical” stages aims to flag disease earlier, using BMI, metabolic markers, and functional impairment. Yet clinicians already view BMI as too crude and are shifting to multidimensional assessments that include fat distribution, comorbidities, and patient‑reported outcomes. A new *Obesity* study of 261,408 treatment‑seeking patients showed up to one‑third would be labeled preclinical under the new framework, even though they are already receiving medical or surgical care. This raises concerns about how clinicians will apply the label in practice.

The reclassification has practical consequences in a market where insurers frequently deny obesity coverage. JAMA’s commentary, supported by the Obesity Medicine Association and EASO, warns that a “preclinical” label gives payers a convenient reason to postpone or refuse bariatric surgery, prescription drugs, or intensive lifestyle programs. By framing the condition as not yet urgent, the terminology risks reinforcing a historic pattern of coverage gaps that delay treatment, worsen health outcomes, and increase long‑term health‑care costs. Patients awaiting care may experience worsening comorbidities during these delays.

To avoid these pitfalls, diagnostic criteria should focus on patient need rather than semantic tiers. Integrating objective data—visceral‑fat imaging, cardiometabolic risk scores, functional capacity—with subjective quality‑of‑life measures can guide reimbursement and clinical decisions. Such a comprehensive framework would keep care pathways open, preventing “watchful waiting” from becoming a default. As obesity rates rise, aligning policy with evidence‑based definitions will support timely access to effective interventions and protect both individual health and system‑wide cost efficiency. Policymakers should also monitor outcomes to refine criteria over time.